ALX Oncology Holdings Q4 2023 GAAP EPS $(0.930) Misses $(0.860) Estimate
Portfolio Pulse from Benzinga Newsdesk
ALX Oncology Holdings (NASDAQ:ALXO) reported Q4 2023 GAAP EPS of $(0.930), missing the consensus estimate of $(0.860) by 8.14%.
March 07, 2024 | 9:22 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
ALX Oncology Holdings reported a Q4 2023 GAAP EPS of $(0.930), missing the consensus estimate by 8.14%.
Earnings misses typically lead to negative investor sentiment in the short term, potentially causing a decrease in stock price. Given the miss was relatively close to estimates, the impact may be moderate but still negative.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100